$MODD

Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.

Modular Medical, Inc. (NASDAQ:MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to its Pivot tubeless patch pump for diabetes patients. The company believes this partnership will broaden patient access and validate its insulin delivery system. Modular Medical aims to simplify diabetes management with its innovative medical device.

Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Modular Medical (NASDAQ:MODD) said it is running a strategic pilot with IMO Health to build an EHR-based, terminology-powered algorithm that identifies diabetes patients likely to benefit from its Pivot insulin pump. The pilot will use clinician-guided phenotypes and IMO Health terminology value sets, supporting a planned Pivot commercial launch in Q4 2026.

Modular Medical, Inc. (Nasdaq: MODD) announced that its CEO, Jeb Besser, will present at Tribe Public's webinar "From FDA Wins to Scaling Manufacturing - What Investors Should Watch" on Friday, May 1, 2026. The event will focus on Modular Medical's newly FDA-cleared Pivot insulin patch pump, designed to make insulin delivery more accessible and affordable for the 4.8 million Americans with diabetes. Investors are encouraged to register to learn about the company's commercial and manufacturing timelines, as well as its strategy to target the large underserved market of individuals currently using multiple daily injections.

Modular Medical (NASDAQ: MODD) announced a free webinar titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch" featuring CEO Jeb Besser on May 1, 2026. The webinar will discuss the company's Pivot tubeless insulin patch pump, which received FDA 510(k) clearance, and its commercialization and manufacturing timelines. This event comes as only 20% of the 4.8 million insulin-dependent diabetics in the U.S. currently use an insulin pump, highlighting a significant market opportunity for Modular Medical's innovative device.

Modular Medical, Inc. (NASDAQ:MODD) announced the pricing of a registered direct offering of 750,000 shares of its common stock at $4.50 per share, aiming to raise approximately $3.4 million in gross proceeds. The offering is expected to close around April 21, 2026, with Maxim Group LLC acting as the sole placement agent. The company specializes in patient-centric insulin delivery technology and seeks to make high-quality glycemic control more accessible and affordable.

Modular Medical, Inc. director and ten percent owner C. Frank Morgan received fully vested stock options to purchase an additional 312 shares of common stock as compensation. The options were granted under the company’s Outside Director Compensation Plan with an exercise price of $4.55 per share and are immediately exercisable, reflecting a neutral filing impact and sentiment. This Form 4 filing details two separate grants for 62 and 250 shares, both expiring on March 31, 2036.